Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Cash from Financing Activities (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Cash from Financing Activities data on record, last reported at -$18.4 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 45.71% year-over-year to -$18.4 million; the TTM value through Dec 2025 reached -$67.4 million, up 16.71%, while the annual FY2025 figure was -$67.4 million, 16.71% up from the prior year.
  • Cash from Financing Activities reached -$18.4 million in Q4 2025 per AMPH's latest filing, down from -$4.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $428.1 million in Q2 2023 and bottomed at -$47.1 million in Q4 2023.
  • Average Cash from Financing Activities over 5 years is $12.1 million, with a median of -$13.6 million recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: plummeted 3730.84% in 2021, then skyrocketed 43169.52% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at -$8.7 million in 2021, then tumbled by 85.86% to -$16.2 million in 2022, then tumbled by 191.32% to -$47.1 million in 2023, then rose by 28.12% to -$33.8 million in 2024, then skyrocketed by 45.71% to -$18.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$18.4 million in Q4 2025, -$4.3 million in Q3 2025, and -$30.2 million in Q2 2025.